ARGOBIO
- Company typePrivate
- Founded2021
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
ARGOBIO firmographics
Firmographics- Name
- ARGOBIO
- Legal name
- Argobio SAS
- Website
- https://argobiostudio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
ARGOBIO industry classification
Industry- Product category
- Biotech Company Creation and Venture Building
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Investment Advice (6282)
- akta.pro primary industry
- Accelerators & Incubators (Investor-Operated) (FSANAAAM)
- akta.pro secondary industry
- Corporate Venture Studios & Incubators (Build/launch ventures) (FSANAHAC)
Keywords
Where ARGOBIO is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
ARGOBIO business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Venture Building Services: ARGOBIO generates returns through equity ownership in portfolio companies it creates and co-founds. The company incubates early-stage therapeutic projects and retains ownership stakes that appreciate as portfolio companies secure subsequent funding rounds and achieve milestones.
- Investment Syndicate Management: ARGOBIO is sponsored by five strategic investors (Kurma Partners, Bpifrance, Angelini Ventures, Evotec, Institut Pasteur) who commit capital to fund company creation activities and have preferential rights to invest in portfolio companies at subsequent financing rounds.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
ARGOBIO product offering
Product offeringCore offering
ARGOBIO is an operational venture builder that creates, incubates, and launches biotech companies from early-stage European academic research in therapeutics. It sources projects from academic partners, secures foundational IP and scientific validation, embeds experienced entrepreneurs-in-residence, and syndicates seed and Series A financing from its investor network to develop investable, de-risked biotech companies across rare diseases, neurological disorders, oncology, and immunology.
Differentiator
Problem solved
Functional benefit
Products and services
- Laigo Bio Biotech company pioneering proprietary SureTACs precision membrane protein degradation platform, developing targeted protein degradation therapies for oncology and immunological indications including autoimmune diseases and graft rejection.
- Crucible Therapeutics Biotech company developing SRSF1-targeting siRNA gene therapy for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), spun out from the University of Sheffield's Department of Neuroscience and Sheffield Institute for Translational Neuroscience (SITraN).
- Kevad Bio Biotech company developing small molecule GDNF mimetics and RET tyrosine kinase activators for the treatment of Parkinson's disease and related neurodegenerative indications.
- Inverna Therapeutics Danish biotech company developing RNA therapeutics using pseudo-exon splicing modulation technology, with a lead program addressing Huntington's disease and additional programs targeting LRRK2 for Parkinson's disease.
- Enodia Therapeutics Biotech company developing small-molecule inhibitors of the SEC61 translocon for targeted protein degradation, leveraging machine learning-enabled selectivity modeling and proteomics-informed secretome analysis for rational drug design.
- Elkedonia Biotech company developing first-in-class, non-hallucinogenic and non-addictive neuroplastogens to address treatment-resistant depression and neuropsychiatric disorders.
- Temper Bio Biotech company developing a long-acting TAFA-4 neurokine analog designed to modulate inflammation both in the circulation and the CNS, with therapeutic potential for chronic inflammatory diseases and neuro-inflammation.
- Thesian Bio Biotech company developing cell-specific in-vivo CAR-T therapy to treat liquid and solid tumors as well as autoimmune disorders.
Companies that use ARGOBIO
Customer profileSegments3 records
Ideal customer profiles3 records
ARGOBIO technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature2 records
ARGOBIO partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered supporting, core and minor.
- EvotecsupportingLife science company providing drug discovery expertise, technologies, and development partnerships. Contributes scientific capabilities and platforms to support ARGOBIO's company creation activities.
- Institut PasteurcoreInternationally renowned biomedical research center in Paris. Key academic partner providing foundational scientific discoveries for portfolio companies including Enodia Therapeutics. Supports technology transfer and company creation from its research.
- Oncode InstitutesupportingDutch oncology research network partnered with ARGOBIO to launch Laigo Bio. Oncode Bridge Fund and Oncology Bridge Fund provide co-funding and support company development to Series A.
- University of SheffieldsupportingPartner institution for Crucible Therapeutics spinout. World-renowned Department of Neuroscience including Sheffield Institute for Translational Neuroscience (SITraN) provides foundational research for SRSF1 targeting ALS/FTD program.
- University of Southern DenmarksupportingCo-founder of Inverna Therapeutics. Professor Brage Storstein Andresen's laboratory provides RNA splicing modulation technology platform for Inverna's RNA therapeutics programs.
- GeneCodeminorEstonian discovery-stage biotech collaborating with ARGOBIO on GDNF mimetics for Parkinson's disease. GeneCode brings small molecule RET tyrosine kinase activator technology for Kevad Bio.
- CIML (Centre d'Immunologie de Marseille-Luminy)supportingResearch institution of Sophie Ugolini providing TAFA-4 neurokine technology for Temper Bio. Ugolini awarded 2023 Impulscience prize (€2.5M) supporting this research.
Scale indicators4 records
Recent moves15 records
Expansion highlights5 records
ARGOBIO competitors and assessment
Company assessmentDirect peers
- Apollo Therapeutics: UK-based therapeutic venture builder backed by AstraZeneca, GSK, Johnson & Johnson, and Oxford/Cambridge universities. Directly comparable to ARGOBIO as an investor-operated biotech startup studio creating companies from top-tier academic research.
- Evotec (BridgeLabs): Evotec operates BridgeLabs, a drug discovery venture builder that creates and incubates therapeutic companies from academic research. Notable because Evotec is both an investor in ARGOBIO and a competitor pursuing similar academic-to-company translation in Europe.
- CRT Pioneer Fund: Cancer Research UK's venture builder that funds and develops oncology-focused spinouts from UK universities. Directly comparable biotech startup studio model with academic sourcing and operational company creation.
- BioGeneration Ventures (BGV): European early-stage life sciences VC firm specializing in creating and investing in biotech companies from academic research. Closely comparable investor model focused on European biotech seed and Series A opportunities.
- Medicxi: European biotech-focused venture capital firm founded by former Index Ventures life sciences team. Similar thesis of building biotech companies from European academic science with operational support.
- Sofinnova MD Start: Sofinnova's early-stage biotech creation platform that incubates therapeutic companies from academic research before Series A. Operates a comparable model of company creation with European academic sourcing.
- Novo Seeds: Early-stage biotech investment arm of Novo Holdings focused on creating and seeding European biotech companies from academic research. Comparable investor-operator model with European focus on therapeutics.
- Oxford Science Enterprises: Oxford University spinout creation and investment firm that builds and backs deeptech and life sciences companies. Comparable startup studio model focused on translating European academic research into investable companies.
Broad incumbents
- Forbion: Large European life sciences VC firm with multiple funds investing across biotech stages. While not a pure venture builder like ARGOBIO, Forbion frequently co-leads ARGOBIO portfolio company rounds and shares the European biotech thesis.
- Kurma Partners: Paris-based healthcare VC firm that initiated and co-founded ARGOBIO. Kurma serves as parent entity and lead investor in multiple ARGOBIO portfolio companies, with broader biotech VC activities beyond the studio model.
Market position
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
ARGOBIO social profiles
Digital presenceARGOBIO financial estimates
Financial estimateRevenue estimate
Valuation estimate
ARGOBIO leadership team
Management profileNumber of profiles
Profiles7 records
ARGOBIO funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ARGOBIO M&A and investment
M&A and investmentM&A
Investments4 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ARGOBIO
What does ARGOBIO do?
ARGOBIO is an operational venture builder that creates, incubates, and launches biotech companies from early-stage European academic research in therapeutics. It sources projects from academic partners, secures foundational IP and scientific validation, embeds experienced entrepreneurs-in-residence, and syndicates seed and Series A financing from its investor network to develop investable, de-risked biotech companies across rare diseases, neurological disorders, oncology, and immunology.
Is ARGOBIO a public or private company?
ARGOBIO is a private company. It is classified as venture growth investor backed and is currently operating.
When was ARGOBIO founded?
ARGOBIO was founded in 2021. It employs 11 to 50 people.
Where is ARGOBIO based?
ARGOBIO is headquartered in Paris, France, in the Europe region.
How does ARGOBIO make money?
Two revenue lines are on record. Venture Building Services are the primary driver. The others are investment Syndicate Management.
Who are ARGOBIO's main competitors?
Direct peers on record are Apollo Therapeutics, Evotec (BridgeLabs), CRT Pioneer Fund, BioGeneration Ventures (BGV), Medicxi, Sofinnova MD Start, Novo Seeds and Oxford Science Enterprises. Broad incumbents are Forbion and Kurma Partners.
Does ARGOBIO have an API?
No public API is recorded for ARGOBIO.
What industry is ARGOBIO in?
ARGOBIO's product category is Biotech Company Creation and Venture Building. Its primary akta.pro industry code is FSANAAAM, Accelerators & Incubators (Investor-Operated), with a secondary code of FSANAHAC, Corporate Venture Studios & Incubators (Build/launch ventures). Its NAICS code is 541714 and its SIC code is 8731.